Read more...​

 

Bionanotechnology is one of the most strategic pillars of MAXi Technology Group, integrating nanotechnology, biotechnology, materials science and life sciences to create innovative solutions for healthcare, pharmaceuticals, nutraceuticals, diagnostics and advanced biomaterials.

​

At the nanoscale, materials interact with biological systems in unique ways, enabling new possibilities for disease detection, targeted delivery, regenerative therapies, functional ingredients and next-generation healthcare technologies. MAXi leverages this convergence to develop technologies capable of addressing some of the world's most pressing challenges in human health, longevity, precision medicine and sustainable biotechnology.

​

Our approach combines scientific research, technology development, biological validation and commercialization strategies to accelerate the transition from laboratory discoveries to clinically and industrially relevant applications.

Functional Nanoparticles for Life Sciences

Functional nanoparticles are among the most versatile tools in modern healthcare and biotechnology.

​

MAXi develops advanced nanoparticle platforms engineered to interact with biological systems, improve bioavailability, protect sensitive compounds and enhance therapeutic, diagnostic and nutritional performance.

​

Research activities include:

• Nanoparticle engineering

• Surface functionalization

• Controlled-release technologies

• Nanoencapsulation systems

• Bioactive nanoparticle platforms

• Nanostructured carrier systems

• Functional ingredient delivery systems

• Advanced formulation technologies

​

Our development programs explore nanoparticles derived from graphene derivatives, nanocellulose, activated liquid carbon and other advanced materials, creating opportunities for pharmaceutical, nutraceutical and biotechnology applications.

Biosensors & Advanced Diagnostics

Rapid, accurate and accessible diagnostics are essential for the future of healthcare.

​

MAXi develops advanced biosensor technologies capable of detecting biological targets with high sensitivity, specificity and speed.

Our research focuses on:

• Electrochemical biosensors

• Graphene-enabled sensing platforms

• Molecular diagnostics

• Point-of-care technologies

• Digital health integration

• Biomarker detection systems

• Pathogen detection technologies

• Precision diagnostic platforms

​

One of the Group's flagship developments is a graphene-based biosensor platform created in collaboration with scientific and industrial partners. The technology demonstrated performance comparable to conventional molecular diagnostic methods while significantly reducing analysis time, illustrating the transformative potential of nanomaterials in healthcare innovation.

​

These technologies create opportunities for applications in infectious diseases, oncology, veterinary diagnostics, food safety, environmental monitoring and precision healthcare.

Biomaterials & Regenerative Technologies

MAXi develops advanced biomaterials designed to interact with biological tissues, support regeneration and improve clinical outcomes.

​

Research initiatives include:

• Functional biomaterials

• Tissue engineering materials

• Advanced composite biomaterials

• Bioactive scaffolds

• Regenerative medicine technologies

• Implantable material platforms

• Medical device materials

• Smart biointerfaces

​

By combining advanced materials science with biological functionality, MAXi seeks to create next-generation solutions capable of improving quality of life, increasing treatment effectiveness and reducing healthcare costs.

Drug Delivery & Controlled Release Systems

The effectiveness of many pharmaceutical and nutraceutical products depends on their ability to reach specific biological targets safely and efficiently.

​

MAXi develops nanotechnology-enabled delivery systems designed to:

• Improve bioavailability

• Enhance stability of active compounds

• Enable controlled release

• Increase therapeutic efficiency

• Reduce adverse effects

• Protect sensitive molecules

• Support targeted delivery strategies

​

These platforms can be applied across pharmaceuticals, nutraceuticals, functional ingredients and advanced therapeutic products.

Nutraceuticals & Functional Ingredients

The growing convergence between healthcare, nutrition and biotechnology creates new opportunities for innovative functional products.

​

MAXi develops technologies designed to enhance the performance of bioactive compounds, botanical extracts, natural ingredients and nutritional formulations through advanced nanoengineering and delivery systems.

​

Potential applications include:

• Functional foods

• Nutraceutical ingredients

• Dietary supplements

• Natural bioactive compounds

• Performance nutrition

• Healthy aging solutions

• Preventive healthcare products

​

Through nanotechnology and advanced formulation strategies, it becomes possible to improve absorption, stability, efficacy and consumer value.

Translational Biotechnology

Innovation only creates impact when it reaches people.

​

For this reason, MAXi adopts a translational innovation approach, connecting scientific research with product development, regulatory pathways, industrial scale-up and commercialization strategies.

Our objective is to transform scientific discoveries into:

• Intellectual property assets

• Licensed technologies

• Healthcare products

• Diagnostic platforms

• Biomaterial solutions

• Therapeutic technologies

• Nutraceutical innovations

• Biotechnology ventures

​

This approach ensures that innovations developed within our ecosystem can efficiently progress from scientific concept to real-world application.

Global Collaboration for Scientific Advancement

Bionanotechnology is an inherently multidisciplinary field that requires collaboration across scientific, clinical and industrial domains.

​

MAXi maintains active and prospective collaborations with research institutions, innovation centers, healthcare organizations and industrial partners in Brazil, Portugal, the United States and other international markets.

​

Our collaborative ecosystem includes opportunities involving:

• Research institutes and innovation centers

• Universities and academic laboratories

• Healthcare institutions

• Biotechnology companies

• Pharmaceutical organizations

• Nutraceutical manufacturers

• Industrial partners

• Startups and technology ventures

• Government-supported innovation programs

​

These partnerships support scientific discovery, technology validation, workforce development, regulatory advancement, industrial scale-up and global technology transfer.

Building the Future of Healthcare Through Bionanotechnology

The future of healthcare will be increasingly shaped by technologies capable of integrating biology, materials science and nanotechnology.

​

At MAXi, we believe that the next generation of diagnostics, biomaterials, therapeutics and biotechnology platforms will emerge from this convergence.

​

By combining scientific excellence, international collaboration and technology commercialization, we are developing bionanotechnology solutions that have the potential to transform healthcare, improve lives and create lasting global impact.

Science. Innovation. Life.